WDM(SH:600055) Zheng Quan Zhi Xing·2025-08-22 16:49Core Viewpoint - The report discusses the stock option incentive plan of Beijing Wandong Medical Technology Co., Ltd. for 2025, detailing the approval process and compliance with relevant regulations [1][2][3]. Summary by Sections 1. Definition and Terms - The report defines key terms related to the stock option incentive plan, including "incentive objects," "grant date," "exercise price," and "exercise conditions" [1]. 2. Approval Process - The company held multiple meetings to approve the stock option incentive plan, including the sixth meeting of the tenth board of directors on March 20, 2025, and the sixth meeting of the tenth supervisory board on the same day [4][5]. - The plan was publicly disclosed from March 28 to April 8, 2025, with no objections raised by employees [4]. - The annual shareholders' meeting on April 16, 2025, approved the plan and authorized the board to handle related matters [4]. 3. Compliance and Conditions - The independent financial advisor confirmed that the incentive plan met all necessary conditions and approvals as per the regulations [6][8]. - The report outlines that the company and the incentive objects have not encountered any disqualifying circumstances as per the management regulations [7]. 4. Granting Details - A total of 120 stock options were granted to 14 core personnel, representing 11.11% of the total options planned for issuance [8]. - The total number of stock options involved in the incentive plan does not exceed 1% of the company's total equity [8]. 5. Financial Impact - The independent financial advisor recommends that the company account for the expenses related to the stock option plan in accordance with relevant accounting standards, noting potential dilution effects [8]. 6. Conclusion - The independent financial advisor concludes that the stock option incentive plan has obtained the necessary approvals and complies with all relevant laws and regulations, ensuring no harm to the company or its shareholders [9].